2007
DOI: 10.1002/cncr.22872
|View full text |Cite
|
Sign up to set email alerts
|

Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995–2004

Abstract: BACKGROUND. There are very limited data concerning survival from prostate cancer among Asian subgroups living in the U.S., a large proportion of whom reside in California. There do not appear to be any published data on prostate cancer survival for the more recently immigrated Asian subgroups (Korean, South Asian [SA], and Vietnamese). METHODS. A study of prognostic factors and survival from prostate cancer was conducted in non‐Hispanic whites and 6 Asian subgroups (Chinese, Filipino, Japanese, Korean, SA, and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
74
3

Year Published

2008
2008
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 70 publications
(83 citation statements)
references
References 32 publications
6
74
3
Order By: Relevance
“…3). The OS results were consistent across the prognostic and geographic subgroups evaluated, including age (<75, 75 years), PSA levels (<median value, median value), bone metastases (4,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)21), and bisphosphonate use (Fig. 4).…”
Section: Resultsmentioning
confidence: 57%
See 1 more Smart Citation
“…3). The OS results were consistent across the prognostic and geographic subgroups evaluated, including age (<75, 75 years), PSA levels (<median value, median value), bone metastases (4,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)21), and bisphosphonate use (Fig. 4).…”
Section: Resultsmentioning
confidence: 57%
“…Interestingly, epidemiological studies have shown Asian populations with prostate cancer, whether residing in Asia or in the United States, to have better OS rates than Caucasian patient populations located in the same geographical region, which could indicate a genetic rather than geographical basis for these differences. 17,18 The influence of genetic background on CRPC progression and response to therapy remains an unquantifiable variable in clinical trial design and holds the greatest promise for understanding the disease. Collectively, these differences highlight the need for new and class-specific endpoints, more reflective of mechanisms of action, to better facilitate the design of clinical trials and inform treatment decisions.…”
Section: Discussionmentioning
confidence: 99%
“…[10][11][12][13][14] In the majority of them, SES remained an independent determinant of mortality even after adjustment for clinical and treatment factors, indicating a residual effect not explained by differences in the healthcare received. 3,30,33,34 However, a great heterogeneity exists among the SES indicators used and the variables chosen to adjust for confounding and that may explain the divergence with the results of the current study. Furthermore, in studies in which access to healthcare was considered to be equivalent among men of different SES, no association has been observed.…”
Section: Gleason Gradementioning
confidence: 74%
“…Although the evidence base for the benefits of screening and treatment options is not yet fully developed for prostate cancer, PSA screening with or without digital rectal examination and curative treatments such as prostatectomy and radiotherapy have been shown to be major determinants of outcome. 13,[30][31][32][33] Lead time and length time biases linked to early detection through PSA screening may partially explain the survival advantage observed among patients with a high SES. However, we found that the differences based on SES in prostate cancer mortality were limited to patients with advanced disease, for whom the impact of such biases is definitively less strong; on the contrary, the choice of treatment most likely plays a more important role.…”
Section: Gleason Gradementioning
confidence: 99%
“…Recent studies have suggested possible racial or ethnic differences in the survival rates of some cancers. (36,37) Aron et al (38) reported that RCC in Asian ⁄ Pacific Islander patients had a significantly higher relative survival rate than all other races ⁄ ethnicities. Recently, the prognoses of 1463 Japanese patients with mRCC treated with cytokines were reported.…”
Section: (A) (B) (C) (D) (E) (F)mentioning
confidence: 99%